Hepatic Encephalopathy

References

1. • Poordad F.F.
   Review article: the burden of hepatic encephalopathy.
   Aliment Pharmacol Ther. 2007; 25: 3-9
   View in Article

   • Google Scholar
2. • Sanyal A.J.
   • Van Natta M.L.
   • Clark J.
   • et al.
   Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.
   N Engl J Med. 2021; 385: 1559-1569
   View in Article

   • Google Scholar
3. • Bustamante J.
   • Rimola A.
   • Ventura P.J.
   • et al.
   Prognostic significance of hepatic encephalopathy in patients with cirrhosis.
   J Hepatol. 1999; 30: 890-895
   View in Article

   • Google Scholar
4. • Bajaj J.S.
   • Duarte-Rojo A.
   • Xie J.J.
   • et al.
   Minimal Hepatic Encephalopathy and Mild Cognitive Impairment Worsen Quality of Life in Elderly Patients With Cirrhosis.
   Clin Gastroenterol Hepatol. 2020; 18 (e2): 3008-3016
   View in Article

   • Google Scholar
5. • Tapper E.B.
   • Halbert B.
   • Mellinger J.
   Rates of and Reasons for Hospital Readmissions in Patients With Cirrhosis: A Multistate Population-based Cohort Study.
   Clin Gastroenterol Hepatol. 2016; 14: 1181-1188 e2
   View in Article

   • Google Scholar
6. • Bajaj J.S.
   The Three Villages of Hepatic Encephalopathy.
   Am J Gastroenterol. 2021; 116: 1184-1186
   View in Article

   • Google Scholar

7. Fabrellas N, Moreira R, Carol M, et al. Psychological Burden of Hepatic Encephalopathy on Patients and Caregivers, Clin Transl Gastroenterol, 11(4), 2020, e00159.

   View in Article

   • Google Scholar
8. • Bajaj J.S.
   • Schubert C.M.
   • Heuman D.M.
   • et al.
   Persistence of cognitive impairment after resolution of overt hepatic encephalopathy.
   Gastroenterology. 2010; 138: 2332-2340
   View in Article

   • Google Scholar
9. • Bauer T.M.
   • Bauer T.M.
   • Steinbruckner B.
   • et al.
   Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis.
   Am J Gastroenterol. 2001; 96: 2962-2967
   View in Article

   • Google Scholar
10. • Dabrowska K.
    • Skowronska K.
    • Popek M.
    • et al.
    Roles of Glutamate and Glutamine Transport in Ammonia Neurotoxicity: State of the Art and Question Marks.
    Endocr Metab Immune Disord Drug Targets. 2018; 18: 306-315
    View in Article

    • Google Scholar
11. • Llansola M.
    • Montoliu C.
    • Agusti A.
    • et al.
    Interplay between glutamatergic and GABAergic neurotransmission alterations in cognitive and motor impairment in minimal hepatic encephalopathy.
    Neurochem Int. 2015; 88: 15-19
    View in Article

    • Google Scholar
12. • Shawcross D.L.
    • Davies N.A.
    • Williams R.
    • et al.
    Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis.
    J Hepatol. 2004; 40: 247-254
    View in Article

    • Google Scholar
13. • Acharya C.
    • Bajaj J.S.
    Gut Microbiota and Complications of Liver Disease.
    Gastroenterol Clin North Am. 2017; 46: 155-169
    View in Article

    • Google Scholar
14. • Chen Y.
    • Yang F.
    • Lu H.
    • et al.
    Characterization of fecal microbial communities in patients with liver cirrhosis.
    Hepatology. 2011; 54: 562-572
    View in Article

    • Google Scholar
15. • Bajaj J.S.
    • Betrapally N.S.
    • Hylemon P.B.
    • et al.
    Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy.
    Hepatology. 2015; 62: 1260-1271
    View in Article

    • Google Scholar
16. • Zhang Z.
    • Zhai H.
    • Geng J.
    • et al.
    Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing.
    Am J Gastroenterol. 2013; 108: 1601-1611
    View in Article

    • Google Scholar
17. • Bajaj J.S.
    • Fagan A.
    • White M.B.
    • et al.
    Specific Gut and Salivary Microbiota Patterns Are Linked With Different Cognitive Testing Strategies in Minimal Hepatic Encephalopathy.
    Am J Gastroenterol. 2019; 114: 1080-1090
    View in Article

    • Google Scholar
18. • Hylemon P.B.
    • Ridlon J.M.
    • et al.
    Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation.
    Am J Physiol Gastrointest Liver Physiol. 2012; 303: G675-G685
    View in Article

    • Google Scholar
19. • Bajaj J.S.
    • Heuman D.M.
    • Hylemon P.B.
    • et al.
    Altered profile of human gut microbiome is associated with cirrhosis and its complications.
    J Hepatol. 2014; 60: 940-947
    View in Article

    • Google Scholar
20. • Jain L.
    • Sharma B.C.
    • Srivastava S.
    • et al.
    Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy.
    J Gastroenterol Hepatol. 2013; 28: 1187-1193
    View in Article

    • Google Scholar
21. • Pryde S.E.
    • Duncan S.H.
    • Hold G.L.
    • et al.
    The microbiology of butyrate formation in the human colon.
    FEMS Microbiol Lett. 2002; 217: 133-139
    View in Article

    • Google Scholar
22. • Wong J.M.
    • de Souza R.
    • Kendall C.W.
    • et al.
    Colonic health: fermentation and short chain fatty acids.
    J Clin Gastroenterol. 2006; 40: 235-243
    View in Article

    • Google Scholar
23. • Peng L.
    • Zhai H.
    • Geng J.
    • et al.
    Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers.
    J Nutr. 2009; 139: 1619-1625
    View in Article

    • Google Scholar
24. • Patidar K.R.
    • Thacker L.R.
    • Wade J.B.
    • et al.
    Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization.
    Am J Gastroenterol. 2014; 109: 1757-1763
    View in Article

    • Google Scholar
25. • Acharya C.
    • Bajaj J.S.
    Current Management of Hepatic Encephalopathy.
    Am J Gastroenterol. 2018; 113: 1600-1612
    View in Article

    • Google Scholar
26. • Duarte-Rojo A.
    • Estradas J.
    • Hernandez-Ramos R.
    • et al.
    Validation of the psychometric hepatic encephalopathy score (PHES) for identifying patients with minimal hepatic encephalopathy.
    Dig Dis Sci. 2011; 56: 3014-3023
    View in Article

    • Google Scholar
27. • Weissenborn K.
    • Amodio P.
    • Bajaj J.
    • et al.
    Neuropsychological characterization of hepatic encephalopathy.
    J Hepatol. 2001; 34: 768-773
    View in Article

    • Google Scholar

28. Saleh ZM, Tapper EB. Predicting which patients with cirrhosis will develop overt hepatic encephalopathy: Beyond psychometric testing, Metab Brain Dis, 2022. Epub ahead of print.

    View in Article

    • Google Scholar
29. • Campagna F.
    • Montagnese S.
    • Ridola L.
    • et al.
    The animal naming test: An easy tool for the assessment of hepatic encephalopathy.
    Hepatology. 2017; 66: 198-208
    View in Article

    • Google Scholar
30. • Bajaj J.S.
    • Hafeezullah M.
    • Franco J.
    • et al.
    Inhibitory control test for the diagnosis of minimal hepatic encephalopathy.
    Gastroenterology. 2008; 135 (e1): 1591-1600
    View in Article

    • Google Scholar
31. • Bajaj J.S.
    • Heuman D.M.
    • Sterling R.K.
    • et al.
    Validation of EncephalApp, Smartphone-Based Stroop Test, for the Diagnosis of Covert Hepatic Encephalopathy.
    Clin Gastroenterol Hepatol. 2015; 13 (e1): 1828-1835
    View in Article

    • Google Scholar
32. • Allampati S.
    • Duarte-Rojo A.
    • Thacker L.R.
    • et al.
    Diagnosis of Minimal Hepatic Encephalopathy Using Stroop EncephalApp: A Multicenter US-Based, Norm-Based Study.
    Am J Gastroenterol. 2016; 111: 78-86
    View in Article

    • Google Scholar
33. • Zeng X.
    • Li X.X.
    • Shi P.M.
    • et al.
    Utility of the EncephalApp Stroop Test for covert hepatic encephalopathy screening in Chinese cirrhotic patients.
    J Gastroenterol Hepatol. 2019; 34: 1843-1850
    View in Article

    • Google Scholar
34. • Acharya C.
    • Shaw J.
    • Duong N.
    • et al.
    QuickStroop, a Shortened Version of EncephalApp, Detects Covert Hepatic Encephalopathy With Similar Accuracy Within One Minute.
    Clin Gastroenterol Hepatol. 2022; 21: 136-142
    View in Article

    • Google Scholar
35. • Bloom P.P.
    • Robin J.
    • Xu M.
    • et al.
    Hepatic Encephalopathy is Associated With Slow Speech on Objective Assessment.
    Am J Gastroenterol. 2021; 116: 1950-1953
    View in Article

    • Google Scholar
36. • Nabi E.
    • Thacker L.R.
    • Wade J.B.
    • et al.
    Diagnosis of covert hepatic encephalopathy without specialized tests.
    Clin Gastroenterol Hepatol. 2014; 12 (e2): 1384-1389
    View in Article

    • Google Scholar
37. • Prasad S.
    • Dhiman R.K.
    • Duseja A.
    • et al.
    Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy.
    Hepatology. 2007; 45: 549-559
    View in Article

    • Google Scholar
38. • Hartmann I.J.
    • Groeneweg M.
    • Quero J.C.
    • et al.
    The prognostic significance of subclinical hepatic encephalopathy.
    Am J Gastroenterol. 2000; 95: 2029-2034
    View in Article

    • Google Scholar
39. • Kappus M.R.
    • Bajaj J.S.
    Covert hepatic encephalopathy: not as minimal as you might think.
    Clin Gastroenterol Hepatol. 2012; 10: 1208-1219
    View in Article

    • Google Scholar
40. • Bajaj J.S.
    • Heuman D.M.
    • Wade J.B.
    • et al.
    Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy.
    Gastroenterology. 2011; 140 (e1): 478-487
    View in Article

    • Google Scholar
41. • Bajaj J.S.
    • Heuman D.M.
    • Sanyal A.J.
    • et al.
    Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.
    PLoS One. 2013; 8: e60042
    View in Article

    • Google Scholar
42. • Sidhu S.S.
    • Goyal O.
    • Mishra B.P.
    • et al.
    Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).
    Am J Gastroenterol. 2011; 106: 307-316
    View in Article

    • Google Scholar
43. • Sharma B.C.
    • Singh J.
    • Srivastava S.
    • et al.
    Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy.
    J Gastroenterol Hepatol. 2017; 32: 1234-1239
    View in Article

    • Google Scholar
44. • Fagan A.
    • Gavis E.A.
    • Gallagher M.L.
    • et al.
    A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study.
    J Hepatol, S0168-8278. 2022; 22: 03116-03126
    View in Article

    • Google Scholar
45. • Montagnese S.
    • Lauridsen M.
    • Vilstrup H.
    • et al.
    A pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy.
    J Hepatol. 2021; 75: 98-107
    View in Article

    • Google Scholar
46. • Vilstrup H.
    • Amodio P.
    • Bajaj J.
    • et al.
    Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.
    Hepatology. 2014; 60: 715-735
    View in Article

    • Google Scholar
47. • Cordoba J.
    • Ventura-Cots M.
    • Simón-Talero M.
    • et al.
    Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF).
    J Hepatol. 2014; 60: 275-281
    View in Article

    • Google Scholar
48. • Bajaj J.S.
    • Cordoba J.
    • Mullen K.D.
    • et al.
    Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement.
    Aliment Pharmacol Ther. 2011; 33: 739-747
    View in Article

    • Google Scholar
49. • Teasdale G.
    • Jennett B.
    Assessment of coma and impaired consciousness. A practical scale.
    Lancet. 1974; 2: 81-84
    View in Article

    • Google Scholar
50. • Ong J.P.
    • Aggarwal A.
    • Krieger D.
    • et al.
    Correlation between ammonia levels and the severity of hepatic encephalopathy.
    Am J Med. 2003; 114: 188-193
    View in Article

    • Google Scholar
51. • Bajaj J.S.
    • Bloom P.P.
    • Chung R.T.
    • et al.
    Variability and Lability of Ammonia Levels in Healthy Volunteers and Patients With Cirrhosis: Implications for Trial Design and Clinical Practice.
    Am J Gastroenterol. 2020; 115: 783-785
    View in Article

    • Google Scholar
52. • Bajaj J.S.
    • Lauridsen M.
    • Tapper E.B.
    • et al.
    Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus.
    Am J Gastroenterol. 2020; 115: 989-1002
    View in Article

    • Google Scholar
53. • Drolz A.
    • Jäger B.
    • Wewalka M.
    • et al.
    Clinical impact of arterial ammonia levels in ICU patients with different liver diseases.
    Intensive Care Med. 2013; 39: 1227-1237
    View in Article

    • Google Scholar
54. • Bajaj J.S.
    • Vargas H.E.
    • Reddy K.R.
    • et al.
    Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis.
    Clin Gastroenterol Hepatol. 2019; 17 (e3): 756-765
    View in Article

    • Google Scholar
55. • Bajaj J.S.
    • Tandon P.
    • O’Leary J.G.
    • et al.
    Admission Serum Metabolites and Thyroxine Predict Advanced Hepatic Encephalopathy in a Multicenter Inpatient Cirrhosis Cohort.
    Clin Gastroenterol Hepatol, S1542-3565. 2022; 22: 00388-00393
    View in Article

    • Google Scholar
56. • Wijdicks E.F.
    Hepatic Encephalopathy.
    N Engl J Med. 2016; 375: 1660-1670
    View in Article

    • Google Scholar
57. • Sharma B.C.
    • Sharma P.
    • Agrawal A.
    • et al.
    Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.
    Gastroenterology. 2009; 137 (891 e1): 885-891
    View in Article

    • Google Scholar
58. • Elwir S.
    • Rahimi R.S.
    Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options.
    J Clin Transl Hepatol. 2017; 5: 142-151
    View in Article

    • Google Scholar
59. • Duong N.K.
    • Shrestha S.
    • Park D.
    • et al.
    Bristol Stool Scale as a Determinant of Hepatic Encephalopathy Management in Patients With Cirrhosis.
    Am J Gastroenterol. 2022; 117: 295-300
    View in Article

    • Google Scholar
60. • Sharma B.C.
    • Sharma P.
    • Lunia M.K.
    • et al.
    A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Am J Gastroenterol. 2013; 108: 1458-1463
    View in Article

    • Google Scholar
61. • Bass N.M.
    • Mullen K.D.
    • Sanyal A.
    • et al.
    Rifaximin treatment in hepatic encephalopathy.
    N Engl J Med. 2010; 362: 1071-1081
    View in Article

    • Google Scholar
62. • Sundaram V.
    • Shaikh O.S.
    Hepatic encephalopathy: pathophysiology and emerging therapies.
    Med Clin North Am. 2009; 93 (vii): 819-836
    View in Article

    • Google Scholar
63. • Shen Y.C.
    • Chang Y.H.
    • Fang C.J.
    • et al.
    Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis.
    Nutr J. 2019; 18: 34
    View in Article

    • Google Scholar
64. • Kircheis G.
    • Luth S.
    Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.
    Drugs. 2019; 79: 23-29
    View in Article

    • Google Scholar
65. • Sidhu S.S.
    • Sharma B.C.
    • Goyal O.
    • et al.
    L-ornithine L-aspartate in bouts of overt hepatic encephalopathy.
    Hepatology. 2018; 67: 700-710
    View in Article

    • Google Scholar
66. • Bajaj J.S.
    • Hassanein T.I.
    • Pyrsopoulos N.T.
    • et al.
    Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-controlled Trials.
    Clin Gastroenterol Hepatol, S1542-3565. 2022; 2022: X
    View in Article

    • Google Scholar
67. • Bajaj J.S.
    • Kassam Z.
    • Fagan A.
    • et al.
    Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial.
    Hepatology. 2017; 66: 1727-1738
    View in Article

    • Google Scholar
68. • Bajaj J.S.
    • Salzman N.H.
    • Acharya C.
    • et al.
    Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial.
    Hepatology. 2019; 70: 1690-1703
    View in Article

    • Google Scholar
69. • Alvares-da-Silva M.R.
    • de Araujo A.
    • Vicenzi J.R.
    • et al.
    Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: A randomized, double-blind, placebo-controlled trial.
    Hepatol Res. 2014; 44: 956-963
    View in Article

    • Google Scholar
70. • Ganapathy D.
    • Acharya C.
    • Lachar J.
    • et al.
    The patient buddy app can potentially prevent hepatic encephalopathy-related readmissions.
    Liver Int. 2017; 37: 1843-1851
    View in Article

    • Google Scholar
71. • Sakurabayashi S.
    • Sezai S.
    • Yamamoto Y.
    • et al.
    Embolization of portal-systemic shunts in cirrhotic patients with chronic recurrent hepatic encephalopathy.
    Cardiovasc Intervent Radiol. 1997; 20: 120-124
    View in Article

    • Google Scholar
72. • Laleman W.
    • Simon-Talero M.
    • Maleux G.
    • et al.
    Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy.
    Hepatology. 2013; 57: 2448-2457
    View in Article

    • Google Scholar
73. • Boike J.R.
    • Thornburg B.G.
    • Asrani S.K.
    • et al.
    North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.
    Clin Gastroenterol Hepatol. 2022; 20 (e36): 1636-1662
    View in Article

    • Google Scholar
74. • Merli M.
    • Giusto M.
    • Lucidi C.
    • et al.
    Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study.
    Metab Brain Dis. 2013; 28: 281-284
    View in Article

    • Google Scholar
75. • Amodio P.
    • Bemeur C.
    • Butterworth R.
    • et al.
    The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus.
    Hepatology. 2013; 58: 325-336
    View in Article

    • Google Scholar
76. • Reuter B.
    • Shaw J.
    • Hanson J.
    • et al.
    Nutritional Assessment in Inpatients With Cirrhosis Can Be Improved After Training and Is Associated With Lower Readmissions.
    Liver Transpl. 2019; 25: 1790-1799
    View in Article

    • Google Scholar
77. • Les I.
    • Doval E.
    • García-Martínez R.
    • et al.
    Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study.
    Am J Gastroenterol. 2011; 106: 1081-1088
    View in Article

    • Google Scholar
78. • Tsai C.F.
    • Chen M.H.
    • Wang Y.P.
    • et al.
    Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
    Gastroenterology. 2017; 152: 134-141
    View in Article

    • Google Scholar
79. • Dam G.
    • Vilstrup H.
    • Watson H.
    • et al.
    Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites.
    Hepatology. 2016; 64: 1265-1272
    View in Article

    • Google Scholar
80. • Bajaj J.S.
    • Cox I.J.
    • Betrapally N.S.
    • et al.
    Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function.
    Am J Physiol Gastrointest Liver Physiol. 2014; 307: G951-G957
    View in Article

    • Google Scholar
81. • Bajaj J.S.
    • Acharya C.
    • Fagan A.
    • et al.
    Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis.
    Am J Gastroenterol. 2018; 113: 1177-1186
    View in Article

    • Google Scholar
82. • Acharya C.
    • Betrapally N.S.
    • Gillevet P.M.
    • et al.
    Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis.
    Aliment Pharmacol Ther. 2017; 45: 319-331
    View in Article

    • Google Scholar
83. • Hajishengallis G.
    Periodontitis: from microbial immune subversion to systemic inflammation.
    Nat Rev Immunol. 2015; 15: 30-44
    View in Article

    • Google Scholar
84. • Bajaj J.S.
    • Lai J.C.
    • Tandon P.
    • et al.
    Role of Oral Health, Frailty, and Minimal Hepatic Encephalopathy in the Risk of Hospitalization: A Prospective Multi-Center Cohort of Outpatients With Cirrhosis.
    Clin Gastroenterol Hepatol, S1542-3565. 2022; 22: 01012-01016
    View in Article

    • Google Scholar
85. • Bajaj J.S.
    • Matin P.
    • White M.B.
    • et al.
    Periodontal therapy favorably modulates the oral-gut-hepatic axis in cirrhosis.
    Am J Physiol Gastrointest Liver Physiol. 2018; 315 (Classification of HE in Four Axes): G824-G837
    View in Article

    • Google Scholar